Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
SanBio Co Ltd (SanBio) carries out the development, production and sales of regenerative cell medicines with cell-based products in various stages of research, development, and clinical trials. The company's pipeline’s products include SB623 which treats traumatic brain injury, dry age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, spinal cord injury, Alzheimer’s disease and others; SB618 targets peripheral nerve damage; SB308 for muscle dystrophy; MSC1 which targets cancer; MSC2 for inflammatory disease and optic neuritis. It operates in the US and Japan. SanBio is headquartered in Chuo-ku, Tokyo, Japan.
Headquarters
Japan
Address
13f, St. Luke Tower, 8-1, Akashi-Cho, Chuo-Ku, Tokyo, 104-0044
Website
www.sanbio.com
Telephone
81 3 62643481
No of Employees
29
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4592 (TYO)
EPS
XYZ
Market Cap*
$1.1B
Net Profit Margin (0 vs)
XYZ
0.0%
* As of and is in US$
SanBio Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Akuugo |
| SB623: | |
| Chronic Ischemic Stroke | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | SanBio Co Ltd | Kidswell Bio Corp | AnGes Inc | Healios KK | CellSeed Inc |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Ibaraki | Chiyoda-Ku | Koto-Ku |
| State/Province | Tokyo | Tokyo | Osaka | Tokyo | Tokyo |
| No. of Employees | 29 | 37 | 56 | 75 | 38 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Toru Kawanishi | Chairman | Executive Board | - | - |
| Keita Mori | Director; President | Executive Board | - | - |
| Shinya Hirata | Corporate Officer; Head - Research and Development | Senior Management | 2022 | - |
| Yoshihiro Kakutani | Corporate Officer; Head - Management Administration | Senior Management | - | - |
| Keizo Nakada | Head - Production; Corporate Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer